Fool - Investing News
02 May 2026, 14:47 UTC · 23w ago
Verdict
Headline leans bullish. We score AXSM +1.00 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
More positive than 99% of ticker scores this week
Search tags
What the story claims
4 claims · scored −1 bearish … +1 bullish
The FDA approved Auvelity for treating agitation associated with Alzheimer's dementia, creating a market opportunity estimated between $1 billion and $2 billion.
More positive than 99% of claims this week
Auvelity is the first non-antipsychotic medication approved for Alzheimer's agitation and lacks the black box warning regarding increased risk of death in elderly patients found on the only other approved treatment.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 98% of claims this week
Needham & Company and TD Cowen have raised their price targets for AXSM to $255 per share following the new approval.
So whatAnalyst upgrades provide a fundamental catalyst for short-term price appreciation and investor confidence.
More positive than 79% of claims this week
Axsome Therapeutics experienced 66% overall sales growth last year, driven primarily by Auvelity, which accounts for nearly 80% of revenue.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company is seeing rapid sales growth, received FDA approval for a new indication for Auvelity, and had price targets raised by analysts.
More negative than 66% of ticker scores this week
Its product Rexulti faces new competition from Axsome's Auvelity, which lacks the black box warning associated with Rexulti.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
1h ago
[mutual] Axsome's Auvelity and Lundbeck's Rexulti both target the treatment of agitation associated with Alzheimer's disease.
−19.6%
Price is moving against the score
$166.00 vs $206.53 close before publication (May 1) · not market-adjusted
AXSM chart →
